ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
TTNPB Promotes Human Pluripotent Stem Cell-to-Neural Stem Cell Transition via Modulation of Chromatin Accessibility and the S-(5'-adenosyl)-L-homocysteine/Choline Metabolic Network.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
Efficient derivation of neural stem cells (NSCs) from human pluripotent stem cells (PSCs) is crucial in regenerative medicine. Here, we report that the combined application of the retinoic acid receptor agonist TTNPB and the GSK3β inhibitor CHIR99021 in a chemically defined medium enabled the induction of a highly advanced NSCs (ANSCs) population from PSCs. ANSCs display robust neuroectodermal gene expression and a heightened capacity for neural lineage commitment. The combination of TTNPB and CHIR99021 markedly enhanced global chromatin accessibility, particularly at neuroectoderm-specific regulatory elements such as PAX6 and SOX1, in parallel with reduced accessibility at the loci of pluripotency factors. Notably, TTNPB alone also exerts a marked effect in enhancing chromatin accessibility. Untargeted metabolomic analysis identified a distinct neural-ectoderm associated metabolic state in ANSCs, prominently characterized by elevated choline, alongside S-(5'-adenosyl)-L-homocysteine, adenosine 5'-diphosphate, and glutathione. Exogenous addition of these metabolites was sufficient to induce neuroectodermal marker expression, highlighting the instructive role of the metabolic network in neural fate induction. Moreover, functional studies showed that ANSCs enabled engraftment into depressed rat hippocampi and restored depression-like behavioral deficits. Our study presents a novel small-molecule strategy that leverages TTNPB-centered epigenetic remodeling and metabolic reprogramming as dual mechanisms driving neural differentiation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.